Viridian Therapeutics, Inc./DE Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Viridian Therapeutics, Inc./DE (VRDN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 6.27 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-02-26
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2016-12-31 was -81.01K shares, a 1861.17% decline year-over-year.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2016-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2016-06-30 was 72.00K shares, a 1957.14% increase year-over-year.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2016-03-31 was 14.80K shares, a 48.97% decline year-over-year.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 6.27M shares.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2016 was 5.79K shares, a 98.87% decline from fiscal 2015.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2015 was 513.40K shares, a 232.30% increase from fiscal 2014.
- Viridian Therapeutics, Inc./DE share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2014 was 154.50K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 6.27M shares 10-K · filed 2026-02-26 | |||
| 2016-12-31 | -81.01K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-24 | -81.01K shares derived: sum of 2 quarters · filed 2017-03-24 | -9.01K shares derived: sum of 3 quarters · filed 2017-03-24 | 5.79K shares 10-K · filed 2017-03-24 |
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | 72.00K shares derived: sum of 2 quarters · filed 2016-10-26 | 86.80K shares 10-Q · filed 2016-10-26 | 91.40K shares derived: sum of 4 quarters · filed 2016-10-26 |
| 2016-06-30 | 72.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | 86.80K shares 10-Q · filed 2016-08-15 | 91.40K shares derived: sum of 3 quarters · filed 2016-08-15 | 567.70K shares derived: sum of 4 quarters · filed 2016-08-15 |
| 2016-03-31 | 14.80K shares 10-Q · filed 2016-05-16 | 19.40K shares derived: sum of 2 quarters · filed 2016-05-16 | 495.70K shares derived: sum of 3 quarters · filed 2016-05-16 | 499.20K shares derived: sum of 4 quarters · filed 2016-05-16 |
| 2015-12-31 | 4.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-21 | 480.90K shares derived: sum of 2 quarters · filed 2016-03-21 | 484.40K shares derived: sum of 3 quarters · filed 2016-03-21 | 513.40K shares 10-K · filed 2016-03-21 |
| 2015-09-30 | 476.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | 479.80K shares derived: sum of 2 quarters · filed 2015-11-13 | 508.80K shares 10-Q · filed 2015-11-13 | |
| 2015-06-30 | 3.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | 32.50K shares 10-Q · filed 2015-08-14 | ||
| 2015-03-31 | 29.00K shares 10-Q · filed 2015-05-15 | |||
| 2014-12-31 | 154.50K shares 10-K · filed 2015-03-27 | |||
| 2014-09-30 | 54.00K shares 10-Q · filed 2014-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |